Bicara Therapeutics (BCAX) Operating Leases (2023 - 2026)

Bicara Therapeutics' Operating Leases history runs 4 years deep, the most recent figure standing at $301000.0 for Q1 2026.

• On a quarterly basis, Operating Leases changed N/A year-over-year to $301000.0 in Q1 2026; TTM through Mar 2026 was $301000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $593000.0, up 352.67% from the prior year.
• Operating Leases fell to $301000.0 in Q1 2026 per BCAX's latest filing, from $593000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $1.2 million in Q2 2025 and bottomed at $131000.0 in Q4 2024.
• The 4-year median for Operating Leases is $372000.0 (2023), against an average of $511142.9.
• Across the five-year window, Operating Leases sank 64.78% in 2024 and surged 542.34% in 2025, its largest moves.
• Year by year, Operating Leases stood at $372000.0 in 2023, then sank by 64.78% to $131000.0 in 2024, then jumped by 352.67% to $593000.0 in 2025, then slumped by 49.24% to $301000.0 in 2026.
• Per Business Quant, the three latest BCAX Operating Leases figures stand at $301000.0 (Q1 2026), $593000.0 (Q4 2025), and $880000.0 (Q3 2025).